LobectomyTHYRORALNCT07055191
TOETVA Technique Compared With Anterior Cervical Thyroidectomy (AC) in Terms of Efficacy and Safety
A study testing Transoral Endoscopic Thyroidectomy by Vestibular Approach and Anterior Cervical thyroidectomy in people with Lobectomy and Thyroidectomy, run by University Hospital, Lille at 10 sites in France.
Trial summary
Nearly 50,000 thyroidectomies are performed in France each year for benign and malignant pathologies. Each one affects the life of the patient and represents, for some, suffering, symbolized by the stigma of the operation. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Lobectomy, Thyroidectomy
- What is being tested?
- Transoral Endoscopic Thyroidectomy by Vestibular Approach and Anterior Cervical thyroidectomy
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 616 participants
- Where
- 10 sitesFrance
- Study dates
- 7 Nov 2025to Nov 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients with a surgical indication for lobectomy or thyroidectomy
- Estimated thyroid volume measured by ultrasonography of less than 60 mL
- Nodules suspected to be malignant measuring less than 4 cm
- Patient aged between 18 and 65 years old
- Patient who has benefited from an endocrinological evaluation, with a favorable opinion for TOETVA or AC Patient who understands and accepts the need for follow-up
- Patient who agrees to be included in the study and who signs the informed consent form
- Patient affiliated to a healthcare insurance plan
Who cannot join
- Patients refusing an alternative to AC or refusing AC
- History of cervical surgery
- Associated parathyroid surgery
- Identification of malignant lymph nodes
- Presence of a severe and evolutive life threatening pathology
- Patients with unstable psychiatric disorder, under supervision or guardianship
Show all 11Show fewer
- Patient who does not understand French/ is unable to give consent
- Patient not affiliated to a French or European healthcare insurance
- Patient who has already been included in a trial which has a conflict of interests with the present study
- Pregnant or breast-feeding patient
- Patient incarcerated
Trial locations and contacts
10 sites in 1 country. Contact the study team or a site near you to ask about taking part.
10 sites in 1 country
France10 sites, 10 recruiting
- Not yet recruiting
AP-HP - Hôpital Avicennes
Bobigny
Christophe Tresallet, Doc., +33(0)1 48 02 61 95, christophe.tresallet@aphp.fr
- Not yet recruiting
Hôpital Franco-Britannique
Levallois-Perret
Grégoire Deroide, Doc., +33(0)1 56 83 08 84, gregoire.deroide@gmail.com
- Recruiting
CHU de Lille, Hôpital Huriez
Lille
Robert Caiazzo, Prof., +33(0)320445515, robert.caiazzo@chu-lille.fr
- Not yet recruiting
CHU Dupuytren
Limoges
Muriel Mathonnet, Prof., +33(0)5 55 05 62 12, mathonnet@unilim.fr
- Not yet recruiting
CHU de Nantes - Hôtel Dieu
Nantes
Eric Mirallié, Prof., +33(0)2 40 08 31 66, eric.mirallie@chu-nantes.fr
- Not yet recruiting
AP-HP - Hôpital Cochin
Paris
Martin Gaillard, Doc., +33(0)1 58 41 17 58, martin.gaillard@aphp.fr
- Not yet recruiting
Hôpital Lyon Sud
Pierre-Bénite
Laure Maillard, Doc., +33(0)4 78 86 23 70, laure.maillard@chu-lyon.fr
- Not yet recruiting
CHU de Poitiers
Poitiers
Gianluca Donatini, Doc., +33(0)5 49 44 43 21, Gianluca.donatini@chu-poitiers.fr
- Not yet recruiting
Polyclinique de la Côte Basque Sud
Saint-Jean-de-Luz
Isabelle Honigman-Bueno, Doc., +33(0)5 59 51 63 67, drhonigmanbueno@gmail.com
- Not yet recruiting
CHRU de Nancy Brabois
Vandœuvre-lès-Nancy
Nominé-Criqui Claire, Doc., +33(0)3 83 15 78 26, c.nomine-criqui@chru-nancy.fr
About this study
Official title: Prospective Randomized Multicenter Trial Comparing the Efficacy and Safety of the Transoral Endoscopic Thyroidectomy by Vestibular Approach (TOETVA) Versus Anterior Cervical Thyroidectomy (AC)
Nearly 50,000 thyroidectomies are performed in France each year for benign and malignant pathologies. Each one affects the life of the patient and represents, for some, suffering, symbolized by the stigma of the operation. The consequences of these scars vary according to the patient, their experience and their culture. For example, cervicotomies are particularly badly accepted in Asia since they are supposed to interrupt the fertility meridian. In France, increasing attention is being paid to the global management of a person with some disease. As a disease state may be transitory, the medical team must consider the situation "after the illness" and plan a return to normality. In particular, alternative approaches to cervicotomy have been developed, in which the scar is in a less visible location, at the cost of a more extensive dissection. These techniques include the transaxillary approach, the bi-areolar biaxillary approach and the retroauricular approach. Such procedures, initially developed as an endoscopic approach, have become progressively robotically assisted, to help with the ergonomics of the procedure. Even though robotic assistance initially helped to spread use of these techniques, it has, over time, limited them, first because of higher cost, and second because of the high learning curve (50 to 75 cases). Finally, the transaxillary approach, which is the most commonly performed, has an inherent problem due to the decreased visibility of the noble structures on the contralateral side, leading to frequent subtotal resection.
Since 2014, the Transoral Endoscopic Thyroidectomy by Vestibular Approach (TOETVA) has been developed as an alternative to these robot-assisted procedures. Because this technique offers the surgeon similar access to the anatomical structures on both sides of the trachea and makes it possible to identify the noble structures to be preserved, TOETVA is currently undergoing a more widespread use in France and worldwide and more candidates for are being offered the procedure. TOETVA reduces the need for dissection to reach the thyroid gland. Moreover, this procedure does not require any special equipment, even if robotic assistance has been used in transoral thyroidectomy.
Read more
Just like the electric light was not developed from the continuous improvement of candles, entirely new approaches are sometimes necessary in surgery. The Scientific Committee of the French Association of Endocrine Surgery is convinced that TOETVA, will become more widely used in France, even if this technique is a major departure from the standard approach. However, it is technically more demanding and must, therefore, be evaluated and supervised. This will require a safety study and a comparison with the current reference procedure, the anterior cervical thyroidectomy (AC). The investigators assume, based on our initial experience, that the use of endoscopic equipment and its magnification will allow good visualization of the noble elements (recurrent nerve and parathyroid glands) and that the complication rate of TOETVA will not be higher than that of the reference approach.
The investigators propose to evaluate, through a prospective randomized study, an innovative endocrine surgical technique that has started to be used worldwide. Although this study is in line with the objectives of an evaluation of the pertinence of care by the health authorities, it would be the first assessment of this innovative surgical technique in thyroid surgery. To our knowledge, after an extensive bibliographic search, no prospective multicenter randomized trial comparing TOETVA to AC has yet been performed, even if many cohorts of patients have been reported to have benefited from this approach6.
In this trial, any change to the quality of life will be extensively evaluated. The use of validated scores to quantify pain and quality of life will provide objective information and make it possible to determine the impact of the presence or absence of a scar.
- Conditions
- Lobectomy, Thyroidectomy
- Being tested
- Transoral Endoscopic Thyroidectomy by Vestibular Approach, Anterior Cervical thyroidectomy
- Keywords
- Endocrinology, thyroidectomy, mini-invasive, TransOral Endoscopic Thyroidectomy by Vestibular Approach (TOETVA), Anterior Cervical thyroidectomy (AC)
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Transoral Endoscopic Thyroidectomy by Vestibular ApproachProcedure or surgery
Transoral Endoscopic Thyroidectomy by Vestibular Approach
Anterior Cervical thyroidectomyProcedure or surgery
Anterior Cervical thyroidectomy
| Study group | Role | What they receive |
|---|---|---|
| Transoral Endoscopic Thyroidectomy by Vestibular Approach (TOETVA) | Experimental | Not described Receives: Procedure: Transoral Endoscopic Thyroidectomy by Vestibular Approach |
| Anterior Cervical thyroidectomy (AC) | Active comparator | Not described Receives: Procedure: Anterior Cervical thyroidectomy |
What is being measured
The primary outcome is the main question the study is designed to answer.
To demonstrate the non-inferiority of TOETVA compared to AC in terms of early postoperative complications (during the first 24 hours) in patients with a surgical indication for lobectomy or total thyroidectomy without associated lymph node procedure.
The rate of patients with early postoperative complications defined by the occurrence of at least one of the following events within the first 24 hours:
- Recurrent paralysis, defined by abnormal vocal cord mobility;
- Hypoparathyroidism: defined by calcium level<80 mg/L and/or parathyroid hormone level<15 pg/mL;
- Hematoma: defined by the need for additional surgery to drain the hematoma
Measured: during the first 24 hours
Secondary outcomes (5)
To compare, between the two surgical approaches (TOETVA vs. AC) in patients with a surgical indication for lobectomy or total thyroidectomy without associated lymph node procedure, the rate of mid-term postoperative complications
The rate of patients with mid-term postoperative complications defined by the occurrence of at least one of the following events within the 30 postoperative days:
- Symptomatic hypocalcemia secondary to hypoparathyroidism: defined by initiation of calcium supplementation;
- Hematoma: defined by the a revision surgery for hematoma;
- Infection: defined by revision surgery for infection or the initiation of an antibiotic therapy, apart from perioperative antibiotic prophylaxis for the TOETVA group.
Measured: within 30 days of surgery
To compare, between the two surgical approaches (TOETVA vs. AC) in patients with a surgical indication for lobectomy or total thyroidectomy without associated lymph node procedure, the quality of life at 1 month after surgery
Quality of life scores assessed at 1 month using the 36-Item Short Form Survey (SF-36), the Voice handicap index (VHI) and the Swallowing Impairment Score (SIS) questionnaires.
SF36: score from 0 to 100. Higher scores mean a better outcome. VHI: score from 0 to 120. Higher scores mean a worse outcome. SIS: score from 0 to 24. Higher scores mean a worse outcome.
Measured: at 1 month after surgery
To compare, between the two surgical approaches (TOETVA vs. AC) in patients with a surgical indication for lobectomy or total thyroidectomy without associated lymph node procedure, the quality of life at 6 months after surgery
Quality of life scores assessed at 6 months using the 36-Item Short Form Survey (SF-36), the Voice handicap index (VHI) and the Swallowing Impairment Score (SIS) questionnaires.
SF36: score from 0 to 100. Higher scores mean a better outcome. VHI: score from 0 to 120. Higher scores mean a worse outcome. SIS: score from 0 to 24. Higher scores mean a worse outcome.
Measured: at 6 months after surgery
To compare, between the two surgical approaches (TOETVA vs. AC) in patients with a surgical indication for lobectomy or total thyroidectomy without associated lymph node procedure, the evolution of pain at 1 month after surgery
Change in pain at 1 month from baseline (preoperative assessment), assessed using two validated scores: (1) the visual analogue scale (VAS) in five areas (lower lip, chin, jaw, anterior neck, and cervix/back) and during four actions (swallowing, brushing teeth, speaking, and shaving), which is the only one that has been validated for TOETVA and (2) the DN4 (Neuropathic Pain 4 Questions), which is widely used in the literature.
Measured: at 1 month after surgery
To compare, between the two surgical approaches (TOETVA vs. AC) in patients with a surgical indication for lobectomy or total thyroidectomy without associated lymph node procedure, the evolution of pain at 6 months after surgery
Change in pain at 6 months from baseline (preoperative assessment), assessed using two validated scores: (1) the visual analogue scale (VAS) in five areas (lower lip, chin, jaw, anterior neck, and cervix/back) and during four actions (swallowing, brushing teeth, speaking, and shaving), which is the only one that has been validated for TOETVA and (2) the DN4 (Neuropathic Pain 4 Questions), which is widely used in the literature.
Measured: at 6 months after surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Jul 2025
- Study start7 Nov 2025
- Primary completionNov 2028 (estimated)
- Study completionNov 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for LobectomyStudies of the same condition, open and under way.
- More trials run by University Hospital, LilleThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 616 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Lille
- Sponsor type
- University, hospital or other
- Collaborators
- Ministry of Health, France
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07055191
- Sponsor's protocol ID
- 2022_0509
- Other IDs
- PHRC-21-0340, 2022-A02301-42
- Acronym
- THYRORAL
- Status last verified
- Jan 2026
- First submitted
- 3 Mar 2025
- Last updated
- 16 Jan 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prospective Randomized Multicenter Trial Comparing the Efficacy and Safety of the Transoral Endoscopic Thyroidectomy by Vestibular Approach (TOETVA) Versus Anterior Cervical Thyroidectomy (AC)
- ClinicalTrials.gov ID
- NCT07055191
- Acronym / sponsor ID
- THYRORAL / 2022_0509
- Conditions
- Lobectomy, Thyroidectomy
- Keywords
- Endocrinology, thyroidectomy, mini-invasive, TransOral Endoscopic Thyroidectomy by Vestibular Approach (TOETVA), Anterior Cervical thyroidectomy (AC)
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 616 participants (estimated)
- Lead sponsor
- University Hospital, LilleUniversity, hospital or other
- Collaborators
- Ministry of Health, France
- Study start
- 7 Nov 2025 (actual)
- Primary completion
- Nov 2028 (estimated)
- Study completion
- Nov 2028 (estimated)
- First posted
- 8 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Nearly 50,000 thyroidectomies are performed in France each year for benign and malignant pathologies. Each one affects the life of the patient and represents, for some, suffering, symbolized by the stigma of the operation. The consequences of these scars vary according to the patient, their experience and their culture. For example, cervicotomies are particularly badly accepted in Asia since they are supposed to interrupt the fertility meridian. In France, increasing attention is being paid to the global management of a person with some disease. As a disease state may be transitory, the medical team must consider the situation "after the illness" and plan a return to normality. In particular, alternative approaches to cervicotomy have been developed, in which the scar is in a less visible location, at the cost of a more extensive dissection. These techniques include the transaxillary approach, the bi-areolar biaxillary approach and the retroauricular approach. Such procedures, initially developed as an endoscopic approach, have become progressively robotically assisted, to help with the ergonomics of the procedure. Even though robotic assistance initially helped to spread use of these techniques, it has, over time, limited them, first because of higher cost, and second because of the high learning curve (50 to 75 cases). Finally, the transaxillary approach, which is the most commonly performed, has an inherent problem due to the decreased visibility of the noble structures on the contralateral side, leading to frequent subtotal resection.
Since 2014, the Transoral Endoscopic Thyroidectomy by Vestibular Approach (TOETVA) has been developed as an alternative to these robot-assisted procedures. Because this technique offers the surgeon similar access to the anatomical structures on both sides of the trachea and makes it possible to identify the noble structures to be preserved, TOETVA is currently undergoing a more widespread use in France and worldwide and more candidates for are being offered the procedure. TOETVA reduces the need for dissection to reach the thyroid gland. Moreover, this procedure does not require any special equipment, even if robotic assistance has been used in transoral thyroidectomy.
Just like the electric light was not developed from the continuous improvement of candles, entirely new approaches are sometimes necessary in surgery. The Scientific Committee of the French Association of Endocrine Surgery is convinced that TOETVA, will become more widely used in France, even if this technique is a major departure from the standard approach. However, it is technically more demanding and must, therefore, be evaluated and supervised. This will require a safety study and a comparison with the current reference procedure, the anterior cervical thyroidectomy (AC). The investigators assume, based on our initial experience, that the use of endoscopic equipment and its magnification will allow good visualization of the noble elements (recurrent nerve and parathyroid glands) and that the complication rate of TOETVA will not be higher than that of the reference approach.
The investigators propose to evaluate, through a prospective randomized study, an innovative endocrine surgical technique that has started to be used worldwide. Although this study is in line with the objectives of an evaluation of the pertinence of care by the health authorities, it would be the first assessment of this innovative surgical technique in thyroid surgery. To our knowledge, after an extensive bibliographic search, no prospective multicenter randomized trial comparing TOETVA to AC has yet been performed, even if many cohorts of patients have been reported to have benefited from this approach6.
In this trial, any change to the quality of life will be extensively evaluated. The use of validated scores to quantify pain and quality of life will provide objective information and make it possible to determine the impact of the presence or absence of a scar.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Transoral Endoscopic Thyroidectomy by Vestibular Approach (TOETVA) | Experimental | Procedure: Transoral Endoscopic Thyroidectomy by Vestibular Approach |
| Anterior Cervical thyroidectomy (AC) | Active comparator | Procedure: Anterior Cervical thyroidectomy |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Patients with a surgical indication for lobectomy or thyroidectomy
- Estimated thyroid volume measured by ultrasonography of less than 60 mL
- Nodules suspected to be malignant measuring less than 4 cm
- Patient aged between 18 and 65 years old
- Patient who has benefited from an endocrinological evaluation, with a favorable opinion for TOETVA or AC Patient who understands and accepts the need for follow-up
Key exclusion criteria (11 listed)
- Patients refusing an alternative to AC or refusing AC
- History of cervical surgery
- Associated parathyroid surgery
- Identification of malignant lymph nodes
- Presence of a severe and evolutive life threatening pathology
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Transoral Endoscopic Thyroidectomy by Vestibular ApproachTransoral Endoscopic Thyroidectomy by Vestibular Approach | Procedure or surgery | Transoral Endoscopic Thyroidectomy by Vestibular Approach (TOETVA) |
| Anterior Cervical thyroidectomyAnterior Cervical thyroidectomy | Procedure or surgery | Anterior Cervical thyroidectomy (AC) |
Primary outcome
To demonstrate the non-inferiority of TOETVA compared to AC in terms of early postoperative complications (during the first 24 hours) in patients with a surgical indication for lobectomy or total thyroidectomy without associated lymph node procedure.
Time frame: during the first 24 hours
The rate of patients with early postoperative complications defined by the occurrence of at least one of the following events within the first 24 hours: * Recurrent paralysis, defined by abnormal vocal cord mobility; * Hypoparathyroidism: defined by calcium level<80 mg/L and/or parathyroid hormone level<15 pg/mL; * Hematoma: defined by the need for additional surgery to drain the hematoma
5 secondary outcomes
To compare, between the two surgical approaches (TOETVA vs. AC) in patients with a surgical indication for lobectomy or total thyroidectomy without associated lymph node procedure, the rate of mid-term postoperative complications
Time frame: within 30 days of surgery
To compare, between the two surgical approaches (TOETVA vs. AC) in patients with a surgical indication for lobectomy or total thyroidectomy without associated lymph node procedure, the quality of life at 1 month after surgery
Time frame: at 1 month after surgery
To compare, between the two surgical approaches (TOETVA vs. AC) in patients with a surgical indication for lobectomy or total thyroidectomy without associated lymph node procedure, the quality of life at 6 months after surgery
Time frame: at 6 months after surgery
To compare, between the two surgical approaches (TOETVA vs. AC) in patients with a surgical indication for lobectomy or total thyroidectomy without associated lymph node procedure, the evolution of pain at 1 month after surgery
Time frame: at 1 month after surgery
To compare, between the two surgical approaches (TOETVA vs. AC) in patients with a surgical indication for lobectomy or total thyroidectomy without associated lymph node procedure, the evolution of pain at 6 months after surgery
Time frame: at 6 months after surgery
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Jan 2026.
Related trials for Lobectomy
Not yet recruitingObservational study
Preoperative Nutritional Status and Postoperative Outcomes in Geriatric Lung Resection
Thoracotomy, Toracosurgery
Not yet recruiting
Postoperative Pulmonary Function Assessment Based on Deep Learning Study
Lung Cancer (NSCLC)
Recruiting
Sodium Oxybate for Postoperative Sleep Disturbance After Thoracic Surgery
Thoracic Surgical Procedures
Not yet recruiting
STAGE-MTC Trial Thyroid Lobectomy With Ipsilateral Central Neck Dissection
Thyroid Gland Medullary Carcinoma
Active, not recruiting
Robot-Assisted vs. Video-Assisted Lobectomy for NSCLC (RAVAR)
Non Small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
10 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Transoral Endoscopic Thyroidectomy by Vestibular Approach and Anterior Cervical thyroidectomy in people with Lobectomy and Thyroidectomy, run by University Hospital, Lille at 10 sites in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 16 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 10 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Robert Caiazzo, Prof. (+33 (0)3 20 44 55 15, robert.caiazzo@chu-lille.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To demonstrate the non-inferiority of TOETVA compared to AC in terms of early postoperative complications (during the first 24 hours) in patients with a surgical indication for lobectomy or total thyroidectomy without associated lymph node procedure. (time frame: during the first 24 hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jan 2026.